Immuneering (IMRX) Profit After Tax (2020 - 2026)

Immuneering's Profit After Tax history runs 7 years deep, the most recent figure standing at -$13.5 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 10.54% year-over-year to -$13.5 million; the TTM figure through Mar 2026 stood at -$54.4 million (up 11.87% YoY), while the FY2025 annual figure was -$56.0 million, up 8.21% from the prior year.
• Profit After Tax was -$13.5 million for Q1 2026 at Immuneering, down from -$11.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$11.5 million in Q2 2022 to a low of -$18.1 million in Q4 2024.
• Historically, Profit After Tax has averaged -$13.8 million across 5 years, with a median of -$13.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax sank 107.02% in 2022, then soared 35.85% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$13.2 million in 2022, then fell by 13.88% to -$15.1 million in 2023, then fell by 19.68% to -$18.1 million in 2024, then soared by 35.85% to -$11.6 million in 2025, then slipped by 16.24% to -$13.5 million in 2026.
• The last three Profit After Tax figures came in at -$13.5 million (Q1 2026), -$11.6 million (Q4 2025), and -$15.0 million (Q3 2025), per Business Quant data.